16m
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a ...
Dr. Sebastian Marx, ITM’s chief business officer and member of the Executive Board, is stepping down effective July 20, 2025 after nearly two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback